Idelalisib plus rituximab improves progression-free survival in relapsed CLL 2 Minute Medicine 1. Idelalisib plus rituximab improved progression-free survival in patients with relapsing CLL compared to rituximab plus placebo. This benefit was seen across all sub-groups regardless of age, gender, or specific mutations. 2. Adverse events ... |
